News | November 14, 2024
AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
The workshop was conducted as a part of the NITI–State workshop series
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Mindset disagrees with and denies the allegations set forth from Reunion.
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
Doctors at Yashoda Hospitals Hyderabad perform rare operation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
